Abstract
Background: Heat shock protein B8 (HSPB8) is expressed in various cancers. However, the functional and clinicopathological significance of HSPB8 expression in bladder cancer (BC) remains unclear. The present study sought to elucidate the clinicopathological features and prognostic value of HSPB8 in BC. Methods: A BC RNA-seq data set was obtained from The Cancer Genome Atlas Urothelial Bladder Carcinoma (TCGA-BLCA) database, and the external validation dataset GSE130598 was downloaded from the GEO database. Samples in the TCGA-BLCA were categorized into two groups based on HSPB8 expression. Differentially expressed genes (DEGs) between the two groups were defined as HSPB8 co-expressed genes. Gene set enrichment analysis (GSEA), protein-protein interaction networks, and mRNA-microRNA (miRNA) interaction networks were generated to predict the function and interactions of genes that are co-expressed with HSPB8. Finally, we examined immune cell infiltration and constructed a survival prediction model for BC patients. Results: The expression level of HSBP8 has a significant difference between cancer samples and normal samples, and its diagnosis effect was validated by the ROC curve. 446 differential expressed genes between HSBP8 high-expression and HSBP8 low expression groups were identified. Gene enrichment analysis and GSEA analysis show that these differential gene functions are closely related to the occurrence and development of BC and the metabolic pathways of BC. The cancer-related pathways included Cytokine-cytokine receptor Interaction, Focal adhesion, and Proteoglycans in cancer. PPI and protein-coding gene-miRNA network visualized the landscape for these tightly bounded gene interactions. Immune cell infiltration shows that B cells, CD4+T cells, and CD8+T cells have strongly different infiltration levels between the HSBP8 high exp group and low exp group. The survival prediction model shows that HSBP8 has strong prognosis power in the BLCA cohort. Conclusion: Identifying DEGs may enhance understanding of BC development’s causes and molecular mechanisms. HSPB8 may play an essential role in BC progression and prognosis and serve as a potential biomarker for BC treatment.
Highlights
Bladder cancer (BC) occurs in the bladder mucosa and is the most common malignancy of the urinary system (Lenis et al, 2020)
We investigated the correlation between Heat shock protein B8 (HSPB8) expression and BC characteristics and analyzed the prognostic role of HSPB8 expression in BC based on RNA-seq data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets
The results indicate that HSPB8 was a good predictive marker (Figure 1G)
Summary
Bladder cancer (BC) occurs in the bladder mucosa and is the most common malignancy of the urinary system (Lenis et al, 2020). It is the fifth most common type of cancer worldwide, with an estimated 81,400 new cases and 17,000 related deaths in the United States in 2020 (Siegel et al, 2020). 75% of patients initially present as NMIBC. Though these patients typically undergo aggressive treatments including, surgery, immunotherapy, chemotherapy, and radiotherapy, the patient response remains variable and unpredictable. About 10–30% of patients with NMIBC may relapse and progress to MIBC (Witjes et al, 2021), and the 5-years overall survival (OS) rate remains unsatisfactory. The present study sought to elucidate the clinicopathological features and prognostic value of HSPB8 in BC
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
